3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Melanoma
15
Neoplasms
7
Colorectal Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Ovarian Neoplasms
4
Solid Tumors
3
Urinary Bladder Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thoracic Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Noonan Syndrome
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Microsatellite Unstable Colorectal Cancer
1
Lung Neoplasms
1
Lung Diseases
1
Leukemia, Myeloid, Acute
1
Hereditary Sensory and Autonomic Neuropathies
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Interventions
relatlimab
1
daratumumab
1
cobimetinib
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Microsatellite Unstable Colorectal Cancer
×
cobimetinib
×
Clear all
NCT02060188
2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2
Completed
385 enrolled
17 charts
2 FDA